Lead Product(s) : Fremanezumab
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Teva’s AJOVY Accepted By FDA For Pediatric Migraine Prevention
Details : Ajovy (fremanezumab) a FDA approved, humanized mAb which selectively binds the calcitonin gene-related peptide (CGRP). It is being investigated for the prevention of migraine in 6-17 years patients.
Product Name : Ajovy
Product Type : Antibody
Upfront Cash : Inapplicable
April 07, 2025
Lead Product(s) : Fremanezumab
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pramipexole Dihydrochloride,Rasagiline Mesylate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Hepion Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Termination
Hepion Ends Merger Agreement with Pharma Two B Ltd.
Details : Hepion and Pharma Two B have terminated their merger agreement. Pharma Two B will continue advancing P2B001 (Pramipexole + Rasagiline), a therapeutic designed to treat Parkinson's disease.
Product Name : P2B001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 11, 2024
Lead Product(s) : Pramipexole Dihydrochloride,Rasagiline Mesylate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Hepion Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : Pramipexole Dihydrochloride,Rasagiline Mesylate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Hepion Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger
Pharma Two B Announces Merger with Hepion and $11.5M Private Placement
Details : Through the merger, the company will operate under Pharma Two B and also advance P2B001 (Pramipexole+Rasagiline), an easy-to-use therapeutic approach, that is designed to address PD.
Product Name : P2B001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 22, 2024
Lead Product(s) : Pramipexole Dihydrochloride,Rasagiline Mesylate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Hepion Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Fremanezumab
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Teva Touts First CGRP Success in Phase III Paediatric Migraine Prevention Study
Details : Ajovy (fremanezumab) a FDA approved, humanized mAb which selectively binds the calcitonin gene-related peptide (CGRP). It is being investigated for the prevention of migraine in 6-17 years patients.
Product Name : Ajovy
Product Type : Antibody
Upfront Cash : Inapplicable
July 19, 2024
Lead Product(s) : Fremanezumab
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fremanezumab
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Teva Announces Phase 3 Evidence of AJOVY® for Migraine Prevention in Children
Details : Ajovy (fremanezumab) is a FDA approved mAb which selectively binds the calcitonin gene-related peptide, it is being investigated for episodic migraine in children and adolescents aged 6-17 years.
Product Name : Ajovy
Product Type : Antibody
Upfront Cash : Inapplicable
July 18, 2024
Lead Product(s) : Fremanezumab
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etilevodopa,Carbidopa
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ND0612 is a continuous, subcutaneous infusion levodopa/carbidopa delivery system under development for patients with Parkinson's disease (PD) and motor fluctuations.
Product Name : ND0612
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 01, 2023
Lead Product(s) : Etilevodopa,Carbidopa
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ropivacaine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Lotus Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRF-110 (ropivacaine) is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended postoperative analgesia.
Product Name : PRF-110
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 05, 2023
Lead Product(s) : Ropivacaine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Lotus Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pramipexole Dihydrochloride,Rasagiline Mesylate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : P2B001 showed superior efficacy to each of its individual components in the trial and comparable efficacy to marketed doses of Pramipexole ER, but with reduced adverse events related to dopaminergic side effects and sleepiness, and with less worsening on...
Product Name : P2B001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 15, 2022
Lead Product(s) : Pramipexole Dihydrochloride,Rasagiline Mesylate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AUSTEDO (deutetrabenazine) safety findings were consistent with findings from the overall OLE study population (n=337), with no new safety concerns from long-term treatment.
Product Name : Austedo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2022
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AUSTEDO (deutetrabenazine) Tablets,is first and only vesicular monoamine transporter 2 inhibitor approved by U.S. Food and Drug Administration in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’...
Product Name : Austedo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 17, 2022
Lead Product(s) : Deutetrabenazine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable